Esperion Therapeutics Inc (NAS:ESPR)
$ 2.195 0.035 (1.62%) Market Cap: 415.87 Mil Enterprise Value: 452.56 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 54/100

Esperion Therapeutics Inc Annual Shareholders Meeting Transcript

May 27, 2021 / 12:00PM GMT
Release Date Price: $20.2 (+1.15%)
Kaitlyn Brosco

Good morning, and welcome to the 2021 Esperion Annual Meeting of Stockholders. I'm Kaitlyn Brosco, Senior Manager, Corporate Communications and Investor Relations. I would now like to turn the meeting over to Sheldon Koenig, President and Chief Executive Officer of Esperion to lead today's events. Mr. Koenig, please go ahead.

Sheldon L. Koenig
Esperion Therapeutics, Inc. - President, CEO & Director

Thank you, Kate, and good morning, everyone. I'd like to welcome you to the 8th Annual Esperion's Stockholders Meeting, which is now called to order. We are excited to be hosting our sixth annual virtual meeting of stockholders, and my first as President and CEO of Esperion. I would just like to say I am honored to be here and confident in the future of this organization. I am incredibly optimistic for the future of our commercial medicines, NEXLETOL and NEXLIZET, and their ability to address a large unmet need within the cardiovascular and LDL-cholesterol lowering space. Even more, I am optimistic for the long-term potential of Esperion as a company,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot